Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000343-53
    Sponsor's Protocol Code Number:BMTCTN2002
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-11-29
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-000343-53
    A.3Full title of the trial
    A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare TGuard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
    Studio in aperto, multicentrico, randomizzato, di fase 3, volto a confrontare T-Guard versus ruxolitinib nel trattamento di pazienti con malattia acuta da trapianto contro ospite refrattaria agli steroidi (SR-aGVHD) di grado III o IV
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to compare the experimental medicine T-Guard to Ruxolitinib for treating acute Graft-versus-Host Disease that does not sufficiently improve
    with the standard steroid treatment
    Si tratta di uno studio volto a confrontare il farmaco sperimentale T-Guard versus Ruxolitinib per il trattamento della malattia acuta da trapianto contro ospite (aGVHD) che non trova sufficientemente miglioramento dalla terapia con steroidi.
    A.3.2Name or abbreviated title of the trial where available
    PROTOCOL BMT CTN 2002
    PROTOCOLLO BMT CTN 2002
    A.4.1Sponsor's protocol code numberBMTCTN2002
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04934670
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorXenikos B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportXenikos B.V.
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationXenikos B.V.
    B.5.2Functional name of contact pointYpke van Oosterhout
    B.5.3 Address:
    B.5.3.1Street AddressWilhelminasingel 14
    B.5.3.2Town/ cityNijmegen
    B.5.3.3Post code6524 AL
    B.5.3.4CountryNetherlands
    B.5.4Telephone number0031243000100
    B.5.5Fax number00310247440155
    B.5.6E-maily.vanoosterhout@xenikos.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name JAKAVI - 5 MG - COMPRESSA - USO ORALE - BLISTER (PVC/PCTFE/ALU) - 56 COMPRESSE
    D.2.1.1.2Name of the Marketing Authorisation holderNOVARTIS EUROPHARM LTD
    D.2.1.2Country which granted the Marketing AuthorisationNetherlands
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameJakavi 5 mg tablets
    D.3.2Product code [042226050]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRuxolitinib
    D.3.9.1CAS number 941678-49-5
    D.3.9.2Current sponsor codeRuxolitinib
    D.3.9.4EV Substance CodeSUB32273
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/05/317
    D.3 Description of the IMP
    D.3.1Product nameUna combinazione di mAb SPV-T3a e mAbWT1 coniugato alla catena A della Proteina Ricina (RTA)
    D.3.2Product code [T-Guard]
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdafsolimab setaritox
    D.3.9.1CAS number 2361013-28-5
    D.3.9.2Current sponsor codeSPV-T3a-RTA
    D.3.9.4EV Substance CodeSUB130328
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNgrisnilimab setaritox
    D.3.9.1CAS number 2361013-29-6
    D.3.9.2Current sponsor codeWT1-RTA
    D.3.9.4EV Substance CodeSUB130329
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD).
    Pazienti con malattia acuta da trapianto contro ospite refrattaria agli steroidi (SR-aGVHD) di grado III o IV.
    E.1.1.1Medical condition in easily understood language
    Acute Graft-versus-Host Disease that does not adequately respond on the regular treatment with corticosteroids
    Malattia acuta da rigetto (Acute Graft Versus Host Disease - aGVHD) che non risponde adeguatamente al trattamento standard con corticosteroidi
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10068908
    E.1.2Term AGVHD
    E.1.2System Organ Class 100000004870
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the rate of complete response (CR) in Grades III and IV SRaGVHD participants on Day 28 post-randomization.
    Determinare il tasso di risposta completa (CR) dei partecipanti con SR-aGVHD di grado III e IV al giorno 28 post-randomizzazione.
    E.2.2Secondary objectives of the trial
    Secondary objectives are the following:
    1. Estimate the overall survival (OS) at Days 60, 90, and 180.
    2. Evaluate the duration of complete response (DoCR).
    3. Estimate the time to complete response (CR) from randomization.
    4. Estimate the overall response rate (CR or partial response (PR)) at Days 14, 28, and 56.
    5. Describe proportions of CR, PR, mixed response (MR), no response (NR), and progression of aGVHD at Days 6, 14, 28, and 56.
    6. Estimate the cumulative incidence of non-relapse mortality (NRM) at Days 90 and 180.
    7. Estimate relapse-free survival at Day 180.
    8. Estimate GVHD-free survival at Days 90 and 180.
    9. Estimate the cumulative incidence of chronic GVHD (cGVHD) at Day 180.
    10. Estimate the cumulative incidence of underlying disease relapse/progression at Day 180.
    11. Describe the incidence of infections.
    12. Describe the incidence of toxicities.
    13. Assess the pharmacokinetics (PK) of T-Guard.
    14. Assess the immunogenicity of T-Guard.
    Gli obiettivi secondari sono i seguenti:
    1.Stimare la OS ai giorni 60, 90 e 180.
    2.Valutare la durata della risposta completa (DoCR).
    3.Stimare il tempo alla risposta completa (CR) dalla randomizzazione.
    4.Stimare il tasso di risposta completa (CR o risposta parziale (PR)) ai giorni 14, 28 e 56.
    5.Descrivere le percentuali di CR, PR, risposta mista (MR), nessuna risposta (NR) e progressione della aGVHD ai giorni 6, 14, 28 e 56.
    6.Stimare l'incidenza cumulativa della mortalità non-recidiva (NRM) ai giorni 90 e 180.
    7.Stimare la sopravvivenza senza recidiva al giorno 180.
    8.Stimare la sopravvivenza senza GVHD ai giorni 90 e 180.
    9.Stimare l'incidenza cumulativa della GVHD cronica (cGVHD) al giorno 180.
    10.Stimare l'incidenza cumulativa della recidiva/progressione della malattia sottostante al giorno 180.
    11.Descrivere l'incidenza delle infezioni.
    12.Descrivere l'incidenza delle tossicità.
    13.Determinare la farmacocinetica (PK) di T-Guard.
    14.Determinare l'immunogenicità di T-Guard.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Patients must be at least 18.0 years of age at the time of consent.
    2. Patient has undergone first allo-HSCT from any donor source or graft source.
    3. Patients diagnosed with Grade III or IV SR-aGVHD after allo-HSCT. SR includes aGVHD initially treated at a lower steroid dose, but must meet
    one of the following criteria:
    • progressed or new organ involvement after 3 days of treatment with methylprednisolone (or equivalent) of greater than or equal to 2 mg/kg/day,
    • no improvement after 7 days of primary treatment with methylprednisolone (or equivalent) of greater than or equal to 2mg/kg/day
    • patients with visceral (GI and/or liver) plus skin aGVHD at methylprednisolone (or equivalent) initiation with improvement in skin GVHD without any improvement in visceral GVHD after 7 days of primary treatment with methylprednisolone (or equivalent) of greater than or equal to 2mg/kg/day
    • Patients who have skin GVHD alone and develop visceral aGVHD during treatment with methylprednisolone (or equivalent) of greater than or
    equal to 1mg/kg/day and do not improve after 3 days of greater than or equal to 2mg/kg/day
    4. Patients must have evidence of myeloid engraftment (e.g., absolute neutrophil count greater than or equal to 0.5 × 109/L for 3 consecutive
    days if ablative therapy was previously used). Use of growth factor supplementation is allowed.
    5. Patients or an impartial witness (in case the patient is capable to provide verbal consent but not capable to sign the informed consent) should have given written informed consent.
    1. I pazienti devono avere almeno 18,0 anni d'età al momento del consenso.
    2. Il paziente è stato sottoposto al primo HSCT allogenico da qualsiasi fonte di donatore o di innesto.
    3. Pazienti con diagnosi di SR-aGVHD di grado III o IV dopo HSCT allogenico. La SR include l'aGVHD inizialmente trattata con una dose inferiore di steroidi, ma deve soddisfare uno dei seguenti criteri:
    • interessamento nuovo o in progressione degli organi dopo 3 giorni di trattamento con metilprednisolone (o equivalente) a una dose maggiore o uguale a 2 mg/kg/giorno,
    • nessun miglioramento dopo 7 giorni di trattamento primario con metilprednisolone (o equivalente) a una dose maggiore o uguale a 2 mg/kg/giorno
    • pazienti con aGVHD viscerale (GI e/o fegato) + cutanea all'inizio del trattamento con metilprednisolone (o equivalente), con miglioramento della GVHD cutanea senza alcun miglioramento della GVHD viscerale dopo 7 giorni di trattamento primario con metilprednisolone (o equivalente) a una dose maggiore o uguale a 2 mg/kg/giorno
    • pazienti che presentano solo una GVHD cutanea e sviluppano un'aGVHD viscerale durante il trattamento con metilprednisolone (o equivalente) a una dose maggiore o uguale a 1 mg/kg/giorno e non migliorano dopo 3 giorni di una dose maggiore o uguale a 2 mg/kg/giorno
    4. I pazienti devono presentare evidenza di attecchimento mieloide (es. conta assoluta dei neutrofili maggiore o uguale a 0,5 × 109/l per 3 giorni consecutivi, se è stata utilizzata in precedenza la terapia ablativa). È consentito l'uso integrativo di fattori di crescita.
    5. I pazienti o un testimone imparziale (nel caso in cui il paziente sia in grado di fornire il consenso verbale, ma non di firmare il consenso informato) devono aver fornito il consenso informato scritto.
    E.4Principal exclusion criteria
    1. Patients who have a creatinine greater than or equal to 2mg/dL or estimated creatinine clearance less than 40 mL/min or those requiring hemodialysis.
    2. Patients who have been diagnosed with active Thrombotic Microangiopathy (TMA), defined as meeting all the following criteria:
    • greater than 4% schistocytes in blood (or equivalent if semiquantitative scale is used e.g., 3+ or 4+ schistocytes on peripheral blood smear),
    • de novo, prolonged or progressive thrombocytopenia (platelet count less than 50 x 109/L or 50% or greater reduction from previous counts),
    • sudden and persistent increase in lactate dehydrogenase concentration greater than 2x ULN,
    • decrease in hemoglobin concentration or increased transfusion requirement attributed to Coombs-negative hemolysis, AND
    • decrease in serum haptoglobin
    3. Patients who have previously received treatment with eculizumab.
    4. Patients who have previously received checkpoint inhibitors (either before or after allo-HCT).
    5. Patients who have been diagnosed with overlap syndrome, that is, with any concurrent features of cGVHD.
    6. Patients requiring mechanical ventilation or vasopressor support.
    7. Patients who have received any systemic treatment, besides steroids, as upfront treatment of aGVHD or as treatment for SR-aGVHD.
    Reinstitution of previously used GVHD prophylaxis agents (e.g., tacrolimus, cyclosporin, MTX, MMF) or substitutes in cases with previously documented intolerance will be permitted. Previous treatment with a JAK inhibitor as part of GVHD prophylaxis or treatment is not allowed.
    8. Patients who have severe hypoalbuminemia, with an albumin of less than or equal to 1 g/dl.
    9. Patients who have a creatine kinase (CK) level of greater than 5 times the upper limit of normal.
    10. Patients with uncontrolled infections. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
    Progression of infection is defined as:
    • hemodynamic instability attributable to sepsis OR
    • new symptoms attributable to infection OR
    • worsening physical signs attributable to infection OR
    • worsening radiographic findings attributable to infection
    11. Patients with evidence of relapsed, progressing, or persistent malignancy, or who have been treated for relapse after transplant, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.
    12. Patients with evidence of minimal residual disease requiring withdrawal of systemic immune suppression.
    13. Patients with unresolved serious toxicity or complications (other than acute GVHD) due to previous transplant.
    14. History of sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD).
    15. Patients with known hypersensitivity to any of the components murine monoclonal antibodies (mAb) or recombinant Ricin Toxin A-chain (RTA).
    16. Patients who have had treatment with any other investigational agent, device, or procedure within 21 days (or 5 half-lives, whichever is greater) prior to enrollment.
    17. Patients who have received more than one allo-HSCT.
    18. Patients with known human immunodeficiency virus infection.
    19. Patients who have a BMI greater than or equal to 35 kg/m2.
    20. Patients who are taking sirolimus must have it discontinued prior to starting study treatment.
    .....For exclusion criteria nr 21-22-23-24 see page 24 of protocol version 0.10 of 21.May.2021
    1. Pazienti che presentano una creatinina > o = a 2 mg/dl o una clearance della creatinina stimata inferiore a 40 ml/min o quelli che richiedono l'emodialisi.
    2. Pazienti in cui è stata diagnosticata una TMA, definita come rispondente a tutti i seguenti criteri:
    • più del 4% di schistociti nel sangue (o equivalente se si usa una scala semiquantitativa, ad esempio 3+ o 4+ schistociti su striscio di sangue periferico),
    • trombocitopenia de novo, prolungata o progressiva (conta delle PLT inferiore a 50 x 109/l o riduzione del 50% o più rispetto alle conte precedenti),
    • aumento improvviso e persistente della concentrazione di LDH superiore a 2x ULN,
    • riduzione della concentrazione di emoglobina o aumento del fabbisogno di trasfusioni attribuito all'emolisi Coombs-negativa, E
    • riduzione dell'aptoglobina sierica
    3. Pazienti che hanno precedentemente ricevuto un trattamento con eculizumab.
    4. Pazienti che hanno ricevuto precedentemente inibitori del checkpoint (prima o dopo l'HCT allogenico).
    5. Pazienti in cui è stata diagnosticata una sindrome da overlap, cioè con qualsiasi caratteristica concomitante di cGVHD.
    6. Pazienti che richiedono ventilazione meccanica o supporto vasopressorio.
    7. Pazienti che hanno ricevuto qualsiasi trattamento sistemico, oltre agli steroidi, come trattamento iniziale dell'aGVHD o come trattamento della SR-aGVHD. Sarà consentita la re-istituzione di agenti di prevenzione della GVHD usati in precedenza (es. tacrolimus, ciclosporina, MTX, MMF) o di sostituti in casi di intolleranza precedentemente documentata. Non è consentito un precedente trattamento con uno JAK-inibitore come parte della profilassi o del trattamento della GVHD.
    8. Pazienti che presentano una grave ipoalbuminemia, con albumina inferiore o uguale a 1 g/dl.
    9. Pazienti che presentano un livello di CK superiore a 5 XULN.
    10. Pazienti con infezioni non controllate. Le infezioni vengono considerate controllate se è stata istituita una terapia appropriata e, al momento dell'arruolamento, non sono presenti segni di progressione. La febbre persistente senza altri segni o sintomi non sarà interpretata come una progressione dell'infezione. La progressione dell'infezione è definita come:
    • instabilità emodinamica attribuibile a sepsi, O
    • nuovi sintomi attribuibili a infezione, O
    • peggioramento dei segni fisici attribuibili a infezione, O
    • peggioramento dei dati radiografici attribuibili a infezione
    11. Pazienti con evidenza di recidiva, progressione o persistenza di una neoplasia maligna, o che sono stati trattati per una recidiva dopo il trapianto, o che potrebbero richiedere una rapida sospensione dell'immunosoppressione come trattamento pre-emergente di una recidiva precoce di neoplasia maligna.
    12. Pazienti con evidenza di malattia residua minima che richiede la sospensione dell'immunosoppressione sistemica.
    13. Pazienti con tossicità o complicanze gravi irrisolte (diverse dalla GVHD acuta) dovute a precedenti trapianti.
    14. Storia di sindrome da ostruzione sinusoidale (SOS)/ malattia veno-occlusiva (VOD).
    15. Pazienti con ipersensibilità nota a uno qualsiasi dei componenti mAbs o catena A della RTA.
    16. Pazienti che hanno ricevuto un trattamento con un qualsiasi altro agente, dispositivo o procedura sperimentale entro 21 giorni (o 5 emivite, a seconda di quale sia il maggiore) prima dell'arruolamento.
    17. Pazienti che hanno ricevuto più di un HSCT allogenico.
    18. Pazienti con infezione nota da virus dell'immunodeficienza umana.
    19. Pazienti che hanno un IMC maggiore o uguale a 35 kg/m2.
    20. Pazienti che assumono sirolimus devono interromperlo prima di iniziare il trattamento dello studio.
    ...Per i criteri di esclusione 22-23-24 si rimanda alla pagina 24 del protocollo versione 0.10 del 21.Mag.2021
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the proportion of participants with a CR on Day 28 after randomization.
    L'endpoint primario é la proporzione di partecipanti con CR al giorno 28 post-randomizzazione.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 28
    Giorno 28
    E.5.2Secondary end point(s)
    Overall Survival (OS) will be assessed at Days 60, 90 and 180 postrandomization.
    Duration of Complete Response (DoCR): DoCR is defined as the time from Day 28 until an aGVHD target organ worsens by at least 1 stage
    and requires a significant escalation in treatment (defined below), or death.
    Time to Complete Response: The time from randomization to first observation of CR will be evaluated.
    Overall Response Rate (ORR): The ORR will be estimated at Days 14, 28, and 56 post-randomization.
    Proportion of Response: Days 6, 14, 28 and 56 post-randomization.
    Non-relapse Mortality (NRM): Days 90 and 180 post-randomization.
    Relapse-free Survival (RFS): Day 180 post-randomization.
    GVHD-free Survival: Days 90 and 180 post-randomization.
    Chronic GVHD (cGVHD): Day 180 post-randomization
    Relapse/Progression of Underlying Malignancy: Day 180 postrandomization
    Incidence of Infections: from randomization to 90 days postrandomization
    Incidence of Toxicities: from randomization to Day 56 postrandomization
    Pharmacokinetics of T-Guard: before each infusion and at the the following post-infusion timepoints: 4, 5, 6, 8, and 24 hours for the first infusion, 4, 6, and 24 hours for the second and third infusions, and 4, 6, 24 and 48 hours for the fourth infusion.
    Immunogenicity of T-Guard: baseline and at Days 6, 14, 28, 90, and 180 after initiation of treatment in T-Guard treated participants only
    La sopravvivenza globale (OS) sarà valutata ai Giorni 60, 90 e 180 post-randomizzazione
    Durata della Risposta Completa (DoCR): La DoCR è definito come il tempo dal Giorno 28 fino a quando un organo bersaglio aGVHD peggiora di almeno 1 stadio e richiede una escalation significativa del trattamento (definito di seguito) o porta alla morte.
    Il tempo alla Risposta Completa: Verrà valutato il tempo dalla randomizzazione alla prima osservazione della CR
    Tasso di risposta globale (ORR): l'ORR sarà stimato nei giorni 14, 28 e 56 dopo la randomizzazione.
    Proporzione di risposta: giorni 6, 14, 28 e 56 dopo la randomizzazione.
    Mortalità non recidivante (NRM): giorni 90 e 180 dopo la randomizzazione.
    Sopravvivenza libera da recidive (RFS): Giorno 180 dopo la randomizzazione.
    Sopravvivenza senza GVHD: giorni 90 e 180 dopo la randomizzazione.
    GVHD cronica (cGVHD): Giorno 180 dopo la randomizzazione
    Recidiva/progressione del tumore maligno sottostante: giorno 180 dopo la randomizzazione
    Incidenza delle infezioni: dalla randomizzazione ai 90 giorni dopo la randomizzazione
    Incidenza di tossicità: dalla randomizzazione al giorno 56 post-randomizzazione
    Farmacocinetica di T-Guard: prima di ogni infusione e nei successivi tempi post-infusione: 4, 5, 6, 8 e 24 ore per la prima infusione, 4,
    6 e 24 ore per la seconda e terza infusione e 4, 6, 24 e 48 ore per la quarta infusione.
    Immunogenicità di T-Guard: basale e ai giorni 6, 14, 28, 90 e 180 dopo l'inizio del trattamento solo nei partecipanti trattati con T- Guard
    E.5.2.1Timepoint(s) of evaluation of this end point
    Timepoints are defined under E.5.2
    I tempi sono definiti in E.5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Comparatore: Ruxolitinib
    Comparator: Ruxolitinib
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA52
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Croatia
    Germany
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    United States
    France
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVSL
    LVSL
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 225
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 37
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 180
    F.4.2.2In the whole clinical trial 246
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Nessuno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-03-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-02-08
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2023-01-05
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:40:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA